Karyopharm Therapeutics EBIT

Karyopharm Therapeutics (KPTI) currently reports a EBIT of $-50M as of June 2026. That compares with $-100M in the prior-year period — up 51.6% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Karyopharm Therapeutics's EBIT history and peer comparisons.

Karyopharm Therapeutics's EBIT increased from $-100M to $-50M — a 51.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Karyopharm Therapeutics's EBIT of $-50M is lower than the Healthcare sector average of $23B. That is roughly 100.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Karyopharm Therapeutics reported $-50M in EBIT as of June 2026. That compares with $-100M in the prior-year period — up 51.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-50M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Karyopharm Therapeutics, and consider following KPTI for alerts when major investors trade the stock.